.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Maternal separation stress represents a significant environmental risk factor for the development of neurodevelopmental conditions, including autism spectrum disorder (ASD). Recent research highlights the critical role of blood-brain barrier (BBB) dysfunction in the pathophysiology of these disorders. Specifically, a recent study utilizing a pentoxifylline autism mouse model investigated how this methylxanthine might mitigate behavioral deficits by influencing hippocampal gene expression.
Researchers examined the effects of pentoxifylline (PTX) on male mice subjected to maternal separation stress. This pentoxifylline autism mouse model utilized daily intraperitoneal injections at doses of 10, 20, and 30 mg/kg for two weeks. Consequently, the study performed various behavioral assessments, including the three-chamber sociability test, shuttle box, and marble burying tests. The results demonstrated that PTX significantly improved sociability and social preference indexes. Furthermore, the treatment enhanced passive avoidance memory and reduced repetitive, stereotyped behaviors.
The neuroprotective effects of pentoxifylline likely stem from its ability to regulate the expression of claudins (CLDNs) within the hippocampus. These molecules are vital for maintaining the integrity of the tight junctions in the BBB. In the stressed mice, researchers observed that PTX treatment successfully decreased CLDN1 expression while increasing CLDN3 and CLDN5 gene expression. Therefore, the modulation of these hippocampal tight junction proteins appears to be a primary mechanism through which PTX mitigates autism-like symptoms. This finding is significant because BBB permeability often contributes to the neuroinflammatory state seen in ASD.
While this is a preclinical study, pentoxifylline is already a well-established drug in clinical practice for peripheral vascular diseases. Its ability to cross the blood-brain barrier and exert anti-inflammatory effects makes it a candidate for adjunct therapy in neurodevelopmental conditions. However, clinicians must remember that human trials are necessary to confirm these specific mechanisms and determine appropriate dosages for pediatric populations. Additionally, the drug's safety profile and potential for synergy with existing treatments like risperidone warrant further investigation.
Claudins are transmembrane proteins that form the backbone of tight junctions in the blood-brain barrier. In autism research, alterations in claudin expression are linked to increased BBB permeability, which may allow harmful inflammatory mediators to enter the brain and disrupt neural circuits.
Pentoxifylline improves social interaction, enhances memory, and reduces repetitive behaviors. It likely achieves these effects by restoring the expression of specific hippocampal claudins that stabilize the blood-brain barrier.
No, pentoxifylline is not currently approved as a primary treatment for autism. While some clinical trials have explored it as an adjunct to antipsychotic medications, its use in this context remains experimental and subject to further clinical validation.
Disclaimer: This content is for informational and educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Vahed Dehkordi Z et al. Pentoxifylline, possibly by modulating expression of claudins in the hippocampus attenuates autistic-related behaviours in male mice subjected to maternal separation stress. World J Biol Psychiatry. 2026 Jun 05. doi: 10.1080/15622975.2026.2677901. PMID: 42247219.
Ghaleiha A et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(2):322-330.
StatPearls [Internet]. Pentoxifylline. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559096/
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Preclinical research indicates that pentoxifylline improves social interaction and memory by regulating claudin expression to support BBB integrity....
3 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
